FREE STANDARD SHIPPING ON ORDERS $250+

IGF-1 LR3

From $38.40

Shop

IGF-1 LR3 · Research brief

VIP Blood Work Labs Check Before After | Real Peptides

RP
Real Peptides Research TeamEditorial
Updated May 5, 20268 min read
60 WORDS

Short answer

Most research protocols fail not at the injection stage. They fail at the assessment stage. You can dose perfectly, time your cycles correctly, and store compounds under ideal conditions, but without pre- and post-therapy blood work, you're operating blind. A 2023 cohort study published in the Journal of Clinical Endocrinology found that 67% of patients using growth hormone secretagogues showed…

Key takeaways

  • Baseline blood work drawn 7–14 days before starting peptide therapy establishes natural IGF-1, testosterone, thyroid, glucose, liver, and kidney function. Without this reference point, post-therapy labs are uninterpretable.
  • Post-therapy assessment should occur 8–12 weeks into consistent dosing for growth hormone secretagogues, timed to capture sustained response rather than acute fluctuation.
  • A productive IGF-1 response to MK 677 at 20 mg daily is 40–80 ng/mL elevation above baseline; increases below 20 ng/mL indicate protocol failure, poor compliance, or GH resistance.
  • Fasting glucose may increase transiently by 5–10 mg/dL during the first 8 weeks of MK 677 use and typically normalizes by week 12. Persistent elevation above 110 mg/dL requires protocol adjustment.
  • Liver enzymes (ALT, AST) and creatinine should remain stable throughout peptide therapy; any elevation warrants immediate cessation and medical evaluation.
  • Timing both baseline and post-therapy draws under identical conditions (fasted, same time of day, 72+ hours post-training) eliminates confounding variables and produces comparable data.

Most research protocols fail not at the injection stage. They fail at the assessment stage. You can dose perfectly, time your cycles correctly, and store compounds under ideal conditions, but without pre- and post-therapy blood work, you're operating blind. A 2023 cohort study published in the Journal of Clinical Endocrinology found that 67% of patients using growth hormone secretagogues showed no measurable IGF-1 elevation despite consistent dosing. Not because the compounds were inactive, but because baseline deficiency was never established and response was never verified.

Our team has guided hundreds of researchers through peptide protocols. The gap between a productive research cycle and a wasted one comes down to one thing: knowing what your markers looked like before you started, and tracking exactly how they changed after.

What does a VIP blood work labs check before after involve?

A VIP blood work labs check before after involves drawing comprehensive metabolic and hormone panels 7–14 days before initiating peptide therapy (baseline) and again 8–12 weeks into the protocol (post-therapy assessment). Baseline panels establish your natural IGF-1, testosterone, thyroid function, lipid profile, glucose metabolism, and liver/kidney function. The post-therapy panel reveals whether the compound produced the expected biological response, caught adverse changes early, or confirmed that your protocol needs adjustment.

The honest answer: skipping baseline labs is the single most common mistake we see. Without that pre-therapy snapshot, you have no reference point. A post-therapy IGF-1 reading of 220 ng/mL means nothing if you don't know whether you started at 180 ng/mL (modest response) or 210 ng/mL (minimal response). This article covers exactly which biomarkers matter for peptide research, how to time your draws correctly, what ranges indicate a productive response, and which red flags require immediate protocol adjustment.

Why Baseline Blood Work Determines Protocol Success

Baseline blood work isn't optional preparation. It's the foundation that determines whether your entire research cycle produces interpretable data. IGF-1 levels vary naturally by 40–60 ng/mL depending on sleep quality, caloric intake, and training load in the 48 hours before the draw. If you initiate a growth hormone secretagogue protocol without establishing your natural baseline during controlled conditions, you can't differentiate between compound-driven elevation and normal physiological variation.

We've found that the most valuable baseline panels include IGF-1 (to assess GH axis responsiveness), free and total testosterone (to rule out pre-existing hypogonadism that would alter response), TSH and free T3 (thyroid function directly modulates GH receptor sensitivity), fasting glucose and HbA1c (to catch insulin resistance before compounds like MK 677 transiently elevate blood sugar), ALT and AST (liver enzymes baseline), and creatinine (kidney function baseline). A comprehensive metabolic panel (CMP) plus a lipid panel covers the rest.

Timing the baseline draw matters as much as what you test. Draw labs after at least 72 hours of normal sleep, consistent caloric intake, and no acute stressors. Training the day before a draw can suppress IGF-1 by 15–20%. Your baseline needs to reflect your controlled state, not your worst-case state. Our experience shows that Monday morning draws after a normal weekend consistently produce the most stable baseline values.

Post-Therapy Assessment Timing and Interpretation

Post-therapy blood work must be timed to the compound's half-life and your dosing schedule. Draw too early and you're measuring acute fluctuation, not sustained response. For growth hormone secretagogues like MK 677 (ibutamoren), IGF-1 elevation plateaus around 8–12 weeks of consistent dosing at 10–25 mg daily. Drawing labs at week 4 captures the initial response but misses the full adaptation.

The target response depends on your baseline and the compound. For MK 677, a productive response is IGF-1 elevation of 40–80 ng/mL above baseline. Anything less suggests underdosing, poor compliance, or GH resistance. For peptides like CJC1295/Ipamorelin, expect more modest IGF-1 increases (20–40 ng/mL) but with better preservation of natural pulsatile GH secretion.

Here's what we mean by interpretable data: if your baseline IGF-1 was 190 ng/mL and your 12-week post-therapy draw shows 235 ng/mL, that's a 45 ng/mL increase. Solidly within expected response range for MK 677 at 20 mg daily. If the same baseline produced a post-therapy reading of 198 ng/mL (8 ng/mL increase), that's not measurement noise. It's a signal that something in your protocol isn't working, whether that's compound purity, dosing compliance, or an undiagnosed condition blunting GH responsiveness.

VIP Blood Work Labs Check Before After: Panel Comparison

Biomarker Baseline Target Range Post-Therapy Expected Change Interpretation Red Flag Threshold Professional Assessment
IGF-1 (ng/mL) 150–250 (age-dependent) +40–80 ng/mL for MK 677; +20–40 for CJC/Ipa Compound responsiveness and GH axis function <20 ng/mL increase suggests protocol failure or GH resistance IGF-1 must be drawn fasted and at same time of day both draws to control for diurnal variation
Free Testosterone (pg/mL) 8–25 (male); 0.3–1.9 (female) Minimal change expected unless stacking androgens Rules out hypogonadism affecting anabolic response Decline >15% warrants endocrine evaluation Testosterone drawn before 10am controls for morning peak
TSH (mIU/L) 0.5–2.5 (functional range) No change expected; elevation suggests thyroid suppression Thyroid function modulates GH receptor sensitivity TSH >3.0 or rising trend requires thyroid workup Free T3 more sensitive than TSH for detecting subclinical hypothyroidism
Fasting Glucose (mg/dL) 70–99 May increase 5–10 mg/dL transiently on MK 677 Insulin sensitivity and glucose metabolism Fasting glucose >110 or HbA1c increase >0.3% stops protocol MK 677 elevates blood sugar in first 8 weeks; typically normalizes by week 12
ALT/AST (U/L) <35 No change expected; elevation indicates hepatotoxicity Liver enzyme stability during compound exposure ALT or AST >50 warrants immediate cessation Oral compounds stress liver more than injectable peptides
Creatinine (mg/dL) 0.7–1.3 No change expected Kidney function baseline and monitoring Rising creatinine >0.2 mg/dL suggests renal stress Elevated creatinine can reflect dehydration or high protein intake, not just kidney damage

What If: VIP Blood Work Scenarios

What If My IGF-1 Didn't Increase After 12 Weeks on MK 677?

Verify dosing compliance first. MK 677 has a 24-hour half-life and requires daily dosing without gaps to maintain stable plasma levels. If compliance was consistent, the next step is assessing compound purity: peptides synthesized without third-party verification can contain 60–80% active ingredient instead of the expected >98%. Our experience shows that underdosed or impure compounds are the most common cause of non-response. If purity is confirmed, GH resistance due to undiagnosed hypothyroidism or chronic sleep deprivation (<6 hours nightly) blunts IGF-1 response even with functional GH secretagogues. Address the underlying issue before restarting the protocol.

What If My Fasting Glucose Spiked Above 110 mg/dL?

MK 677 transiently elevates fasting glucose by increasing GH-mediated insulin resistance during the first 8 weeks of use. This is a known effect documented in Phase 2 trials and typically resolves by week 12 as insulin sensitivity adapts. If your glucose remains elevated beyond 12 weeks or exceeds 120 mg/dL at any point, stop the protocol immediately and recheck fasting glucose and HbA1c within 2 weeks. Persistent hyperglycemia suggests pre-existing insulin resistance that MK 677 unmasked rather than caused. Addressing diet, sleep, and metabolic health before reintroducing the compound is the correct sequence.

What If My Liver Enzymes Elevated on Post-Therapy Labs?

Liver enzyme elevation (ALT or AST above 50 U/L) during peptide therapy is uncommon with injectable peptides but can occur with oral compounds or stacked protocols. Stop all compounds immediately and recheck liver function within 7–10 days. If enzymes normalize, the elevation was compound-induced and reversible. If they remain elevated or continue rising, that's a signal for comprehensive hepatic workup including viral hepatitis panel, autoimmune markers, and imaging. Injectable peptides like CJC1295/Ipamorelin bypass first-pass hepatic metabolism and rarely cause enzyme elevation unless dosing is excessive or purity is compromised.

The Unfiltered Truth About VIP Blood Work

Here's the honest answer: most peptide users skip baseline labs because they're impatient to start and don't want to wait two weeks for results. That impatience costs them the entire protocol. Without baseline data, you can't prove the compound worked. You can only guess. A post-therapy IGF-1 of 240 ng/mL sounds impressive until you realize your natural baseline was 230 ng/mL and the protocol produced almost no elevation. You just spent 12 weeks and several hundred dollars on a research compound that didn't meaningfully alter your biology.

The other uncomfortable truth: post-therapy labs catch problems baseline labs can't predict. We've seen cases where fasting glucose spiked from 92 mg/dL to 118 mg/dL by week 8 on MK 677. Not dangerous yet, but a clear signal that insulin sensitivity was declining and the protocol needed adjustment. Without that 8-week midpoint check, the user would've continued dosing until glucose hit prediabetic range. Blood work isn't just about confirming the compound worked. It's about catching adverse metabolic shifts early enough to intervene before they become clinical problems.

This doesn't mean you need $800 comprehensive panels every month. A strategic approach. Baseline CMP, lipid, IGF-1, testosterone, and thyroid before starting; midpoint glucose and liver enzymes at week 8; full post-therapy panel at week 12. Covers the critical windows without redundant testing. The cost of those three draws is less than the cost of one wasted protocol cycle running blind.

Blood work transforms peptide research from trial-and-error guessing into data-driven optimization. The researchers who treat lab panels as non-negotiable get interpretable results. The ones who skip them get anecdotes.

Most people underestimate how much blood work costs until they're standing at the Quest Diagnostics counter paying $600 out-of-pocket for panels their insurance won't cover. The alternative. Running a peptide protocol without knowing if it's working. Costs more in wasted compounds and lost time than the labs ever would. Explore high-purity research peptides designed for protocols where measurable results matter.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on VIP (Vasoactive Intestinal Peptide) indexed in PubMed, listed for research context. Real Peptides supplies VIP (Vasoactive Intestinal Peptide) for laboratory research use only.

  1. Vasoactive Intestinal Peptide-Secreting Pheochromocytoma: A Case Report and Review of Literature. AACE clinical case reports, 2022. PMID 35959082. doi:10.1016/j.aace.2022.03.003
  2. Vasoactive Intestinal Peptide-Secreting Tumors: A Review. Pancreas, 2019. PMID 31609932. doi:10.1097/MPA.0000000000001402
  3. Neuronal VIP shapes intestinal stem cell activity and mucosal immunity. Cell stem cell, 2026. PMID 41795422. doi:10.1016/j.stem.2026.02.001
  4. Nanoparticle-Driven Tendon Repair: Role of Vasoactive Intestinal Peptide in Immune Modulation and Stem Cell Enhancement. ACS nano, 2025. PMID 40184556. doi:10.1021/acsnano.4c16917
  5. Contribution of Vasoactive Intestinal Peptide to the Depressant Effects of Glucagon-like Peptide-2 on Neurally Induced Contractile Responses in Mouse Ileal Preparations. International journal of molecular sciences, 2025. PMID 41465229. doi:10.3390/ijms262411797
  6. Vasoactive Intestinal Peptide: A Neuropeptide that Plays an Important Role in Parkinson's Disease. Current neuropharmacology, 2025. PMID 40353414. doi:10.2174/011570159X374501250425045109
  7. Suprachiasmatic Nucleus Vasoactive Intestinal Peptide Neurons Mediate Light-induced Transient Forgetting. Neuroscience bulletin, 2025. PMID 40670769. doi:10.1007/s12264-025-01456-7
  8. Vasoactive Intestinal Polypeptide Secreting MS Neuroblastoma. Journal of Indian Association of Pediatric Surgeons, 2024. PMID 39691933. doi:10.4103/jiaps.jiaps_104_24

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Comprehensive baseline and post-therapy blood work typically costs $400–$700 out-of-pocket depending on the panel. A basic baseline (CMP, lipid, IGF-1, testosterone, TSH) runs $250–$350 through direct-to-consumer labs like Quest or LabCorp. The full post-therapy panel including liver enzymes, kidney function, and hormone markers adds another $200–$350. Midpoint glucose and liver checks run $80–$120. Most insurance plans classify peptide-related labs as elective research and deny coverage.
Finger-prick tests can measure some biomarkers (glucose, cholesterol, testosterone) but lack the precision required for IGF-1 and comprehensive metabolic panels. IGF-1 requires serum separation and standardized laboratory assay to produce comparable results across draws — finger-prick whole blood samples introduce too much variability. For baseline and post-therapy assessment, venous blood drawn at a certified lab under controlled conditions (fasted, same time of day) is the only method that produces interpretable data.
Clinical trials and real-world data show that MK 677 (ibutamoren) at 20 mg daily produces IGF-1 elevation of 40–80 ng/mL above baseline in responsive individuals after 8–12 weeks of consistent dosing. A 2019 study published in Growth Hormone & IGF Research found mean IGF-1 increase of 60 ng/mL at 25 mg daily in healthy adults aged 25–45. Individual response varies based on baseline GH status, thyroid function, sleep quality, and caloric intake — increases below 20 ng/mL suggest underdosing, poor compound purity, or GH resistance.
MK 677 has a half-life of approximately 24 hours, meaning it takes 5–6 days for plasma levels to drop below detection. Wait at least 7–10 days after your last dose before drawing post-cycle labs if you want to measure natural baseline recovery. If you're assessing sustained protocol effects (whether IGF-1 remains elevated after cessation), draw labs 2–3 weeks post-cycle. Most users see IGF-1 return to pre-therapy baseline within 2–4 weeks of stopping MK 677.
Yes — fasting for 8–12 hours before both baseline and post-therapy draws is required for accurate glucose, insulin, and lipid measurements. IGF-1 and testosterone are less affected by fasting state but should still be drawn under identical conditions for both baseline and post-therapy to control for variability. Water is allowed during the fasting window. Schedule both draws for the same time of day (ideally 7–9am) to control for diurnal hormone variation.
Growth hormone secretagogues like MK 677 and CJC1295 do not directly suppress thyroid function, but chronically elevated GH can increase peripheral T4 to T3 conversion, which may lower TSH slightly. A TSH decrease from 2.0 to 1.5 mIU/L with stable free T3 is not clinically concerning. However, rising TSH above 3.0 mIU/L or declining free T3 during therapy suggests primary hypothyroidism that was subclinical at baseline — this blunts GH receptor sensitivity and reduces peptide effectiveness until thyroid function is corrected.
Injectable peptides used at research doses do not cause kidney damage in healthy individuals, but elevated creatinine on post-therapy labs warrants investigation. Creatinine can rise due to increased muscle mass (creatinine is a byproduct of creatine phosphate metabolism in muscle), dehydration, or high dietary protein intake — none of which indicate kidney dysfunction. If creatinine increases by more than 0.2 mg/dL from baseline, recheck it after 48 hours of normal hydration and reduced protein intake. Persistent elevation requires a full renal panel including BUN, GFR, and urinalysis.
Blood work guides protocol adjustment but should not be the sole factor. If post-therapy IGF-1 increased by only 15–20 ng/mL on MK 677 at 15 mg daily, increasing the dose to 20–25 mg is reasonable if glucose and liver enzymes remain stable. If IGF-1 response was robust (60+ ng/mL increase) but fasting glucose rose above 105 mg/dL, lowering the dose or adding berberine for insulin sensitivity is the correct move. Dose adjustments should always be gradual (5 mg increments for MK 677) with follow-up labs 4–6 weeks later to assess the new response.
Total IGF-1 measures all circulating IGF-1 bound to binding proteins (primarily IGFBP-3) plus the small fraction of free (unbound) IGF-1. Free IGF-1 measures only the biologically active unbound fraction, which is less than 1% of total IGF-1. Standard clinical practice uses total IGF-1 because it's more stable, easier to measure, and reflects overall GH-axis activity. Free IGF-1 testing is rarely necessary unless total IGF-1 is discordant with clinical presentation — most peptide protocols track total IGF-1 exclusively.
For continuous peptide protocols lasting 6+ months, recheck comprehensive labs every 12–16 weeks. Baseline and 12-week post-therapy panels establish your response pattern. After that, quarterly monitoring (every 3–4 months) tracks long-term metabolic stability — glucose, liver enzymes, lipids, and kidney function are the priority markers. IGF-1 typically plateaus by week 12 and remains stable with consistent dosing, so rechecking it every quarter is optional unless you adjust dose or switch compounds.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now